PMID- 23001685
OWN - NLM
STAT- MEDLINE
DCOM- 20140508
LR  - 20161020
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 23
IP  - 5
DP  - 2013 Sep
TI  - Celecoxib does not affect the release of hyaluronic acid in end stage 
      osteoarthritic joints.
PG  - 934-8
LID - 10.1007/s10165-012-0772-0 [doi]
AB  - OBJECTIVES: Non-steroidal anti-inflammatory drugs play a major role in the 
      management of osteoarthritis (OA). However, it remains unknown whether these 
      drugs affect cartilage and synovial metabolism in osteoarthritic joints. The aim 
      of this study was to evaluate the effects of a selective cyclooxygenase (COX)-2 
      inhibitor, celecoxib, on synovial fluids and tissues in severely osteoarthritic 
      knees. METHODS: Patients were randomized into three groups and medicated 
      two weeks prior to total knee arthroplasty with celecoxib, diclofenac sodium, or 
      no medication (control). We checked for the presence of matrix 
      metalloproteinase-3 (MMP-3), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta 
      (IL-1beta), and hyaluronic acid (HA) in the synovial fluids of all three groups. 
      RESULTS: MMP-3 significantly decreased in the celecoxib-treated patients 
      (p = 0.0031). On the other hand, there were no significant differences among the 
      three groups in their TNF-alpha and IL-1beta levels. HA in the joint fluid was 
      significantly increased in the diclofenac-treated group, while HA was not changed 
      in the celecoxib-treated patients. CONCLUSIONS: Our study suggests that celecoxib 
      did not affect the level of HA in the joint fluid in the knee in severe OA, in 
      contrast to the effect of the dual COX inhibitor.
FAU - Takahashi, Daisuke
AU  - Takahashi D
AD  - Department of Joint Replacement and Tissue Engineering, Hokkaido University 
      Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.
FAU - Majima, Tokifumi
AU  - Majima T
FAU - Onodera, Tomohiro
AU  - Onodera T
FAU - Kasahara, Yasuhiko
AU  - Kasahara Y
FAU - Inoue, Masahiro
AU  - Inoue M
FAU - Irie, Toru
AU  - Irie T
FAU - Kasemura, Toshiyuki
AU  - Kasemura T
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120922
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cartilage, Articular/drug effects/metabolism
MH  - Celecoxib
MH  - Cyclooxygenase 2 Inhibitors/pharmacology/*therapeutic use
MH  - Diclofenac/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Hyaluronic Acid/*metabolism
MH  - Interleukin-1beta/metabolism
MH  - Knee Joint/*drug effects/metabolism
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis, Knee/*drug therapy/metabolism
MH  - Pyrazoles/pharmacology/*therapeutic use
MH  - Sulfonamides/pharmacology/*therapeutic use
MH  - Synovial Fluid/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2012/09/25 06:00
MHDA- 2014/05/09 06:00
CRDT- 2012/09/25 06:00
PHST- 2012/03/28 00:00 [received]
PHST- 2012/09/03 00:00 [accepted]
PHST- 2012/09/25 06:00 [entrez]
PHST- 2012/09/25 06:00 [pubmed]
PHST- 2014/05/09 06:00 [medline]
AID - 10.1007/s10165-012-0772-0 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2013 Sep;23(5):934-8. doi: 10.1007/s10165-012-0772-0. Epub 2012 
      Sep 22.